Clinical experience of prophylactic treatment in von Willebrand disease

  • Lethagen S
  • 9


    Mendeley users who have this article in their library.
  • 13


    Citations of this article.


The prophylactic treatment of bleeding in von Willebrand disease (vWD) has a long history in Sweden, having been first initiated in the late 1950s. The clinical experience of the prophylaxis of vWD in Sweden is described in the current review of a retrospective study of 37 patients from three haemophilia centres receiving prophylaxis for vWD. Prophylaxis with a plasma concentrate (fraction I-0 or Factor VIII) effectively reduced the median number of bleeds per year, prevented joint arthropathy in those who started prophylaxis at a young age, and improved the quality of life of all patients with vWD, particularly those with type 3 disease. This study demonstrates that the long-term prophylactic treatment with von Willebrand Factor (vWF)/FVIII concentrate (Haemate-P®, ZLB Behring) in vWD is warranted in the majority of patients with type 3 disease. © 2006 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • Arthropathy
  • Factor VIII concentrate
  • Haemorrhage
  • Prophylaxis
  • Synovitis
  • von Willebrand disease
  • von Willebrand factor

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Stefan Lethagen

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free